Replicor to Disclose Late Breaking HBV Clinical Data at AASLD 2016
Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that the preliminary interim analysis from its latest REP 401 clinical trial has been selected by the American Association for the Study of Liver Disease (AASLD) for presentation during the late-breaking oral abstract session at its annual meeting to be held November 11-15, 2016 in Boston, U.S.A.
The REP 401 protocol (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of its first in class HBsAg release inhibitor, REP 2139 and a REP 2139 derivative with improved plasma and tissue clearance (REP 2165) in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (peg-IFN) in treatment naïve patients with chronic HBeAg negative HBV infection. The selection of Replicor’s clinical data for presentation during the late breaking oral abstract session on November 15th , 2016 highlights the recognition of NAP-based therapy as an important new approach for achieving functional cure in patients with chronic HBV.
Complete 6 month follow-up data from the REP 301 protocol (NCT02233075) assessing the safety and efficacy of REP 2139 in combination with peg-IFN in patients with chronic HBV / HDV co-infection will also be presented during the poster session on November 14th , 2016.
These presentations will expand on the existing clinical data demonstrating the unique ability of NAP-based combination therapy to eliminate serum HBsAg and to achieve functional cure in patients with HBV and HBV / HDV co-infection.
Replicor’s presentations from AASLD 2016 will be available on the company’s website following their disclosure at the meeting at www.replicor.com/science/conference-presentations . For further information about the 2016 AASLD Meeting visit: http://www.aasld.org/events-professional-development/liver-meeting .
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com .
For Replicor Inc.
Alexandra Peterson, 212-508-9709
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-PELLEPHARM20.11.2018 12:02 | Pressemeddelelse
LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases
IDEMIA20.11.2018 10:02 | Pressemeddelelse
IDEMIA Provides SK Telecom in South Korea with GMSA Compliant Smart Connect Solution to Activate and Manage eSIM Device Lifecycles
AURAK20.11.2018 08:53 | Pressemeddelelse
AURAK Hosts ICEWES 2018
IPSEN/3BP20.11.2018 07:32 | Pressemeddelelse
Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
GEMALTO20.11.2018 07:02 | Pressemeddelelse
Gemalto Expands Data Center Footprint in Europe to Support Cloud-Based Access Management Services
UAE-MINISTRY-OF-INTERIOR19.11.2018 22:15 | Pressemeddelelse
Saif bin Zayed Inaugurates Interfaith Alliance for Safer Communities: Child Dignity in the Digital World Forum
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum